weight loss drug news today glp-1 september 2025 WHO adds weight-loss, diabetes drugs to essential medicines list | World Health Organization One of the fastest growing

This type of study combines and analyzes results from multiple previous investigations in this case four observational studies that included nearly 37,000 pregnancies

The search terms are glucagon-like peptide-1 receptor agonist (including exenatide, liraglutide, albiglutide, lixisenatide, semaglutide, dulaglutide, taspoglutide), sodium glucose cotransporter 2 inhibitor (including canagliflozin, empagliflozin, dapagliflozin, ipragliflozin, luseogliflozin, tofogliflozin, remogliflozin, sergliflozin, sotagliflozin, ertugliflozin) and type 2 diabetes mellitus

Zhang T, Cheng JK, Hu YM

GLP-1 receptor agonists and GLP-1/GIP combination therapies have become foundational treatments for type 2 diabetes and obesity

Available from: Kanbay M, Copur S, Guldan M, Ozbek L, Mallamaci F, Zoccali C